PROCEPT BioRobotics (PRCT) Set to Release Quarterly Earnings on Wednesday

Key Points

• PROCEPT BioRobotics is scheduled to report Q3 2026 earnings after the market closes on November 4. Analysts expect a loss of $0.3895 per share and revenue of approximately $100.52 million.
• In the prior quarter, the company reported a $0.47-per-share loss, slightly worse than estimates, while revenue reached $94.50 million, up 19.3% year over year.
• Analyst sentiment is cautious, with a consensus “Hold” rating and a $25.50 price target. The stock recently traded at $19.80, and CEO Larry Wood purchased nearly 24,000 shares in August.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.3895) per share and revenue of $100.52 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. During the same period in the prior year, the business posted ($0.35) earnings per share. PROCEPT BioRobotics's revenue for the quarter was up 19.3% compared to the same quarter last year. On average, analysts expect PROCEPT BioRobotics to post ($1.67) EPS for the current fiscal year and ($1.07) EPS for the next fiscal year.

PROCEPT BioRobotics Price Performance

NASDAQ:PRCT opened at $19.80 on Wednesday. PROCEPT BioRobotics has a one year low of $16.67 and a one year high of $38.11. The company's 50-day simple moving average is $19.49 and its 200 day simple moving average is $23.58. The firm has a market capitalization of $1.13 billion, a P/E ratio of -10.21 and a beta of 0.92.

Analyst Ratings Changes

A number of equities analysts have weighed in on PRCT shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of PROCEPT BioRobotics in a research note on Thursday, October 15th. Jefferies Financial Group reissued a "hold" rating and issued a $20.00 price target on shares of PROCEPT BioRobotics in a research report on Wednesday, August 5th. Oppenheimer restated a "market perform" rating on shares of PROCEPT BioRobotics in a research note on Wednesday, September 9th. UBS Group downgraded PROCEPT BioRobotics from a "buy" rating to a "neutral" rating and set a $20.00 price target on the stock. in a research note on Tuesday, July 28th. Finally, Robert W. Baird set a $20.00 price objective on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Three investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $25.50.

Insider Transactions at PROCEPT BioRobotics

In other news, CEO Larry Wood acquired 23,900 shares of the business's stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the transaction, the chief executive officer owned 23,900 shares of the company's stock, valued at $498,315. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 1,043 shares of company stock valued at $21,851. Insiders own 4.00% of the company's stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company's technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.